awmsg logo



bortezomib (Velcade®)


Reference No. 1254

Publication date:
23/01/2013


Last review date:
30/08/2016

Appraisal information

bortezomib (Velcade®) 3.5 mg powder for solution for subcutaneous injection


Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 07/11/2012
AWMSG meeting date: 12/12/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 3812
Ministerial ratification: 16/01/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Bortezomib (Velcade®) 3.5 mg subcutaneous injection is recommended as an option for use within NHS Wales: - for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for bone marrow transplantation; - in combination with melphalan and prednisone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download